Total income rose 16 percent to Rs 4,091.8 crore in Q1FY19 compared to previous year's Rs 3700 crore.
Aurobindo PharmaÂ Thursday reported 12 percent decline in its June quarter net profit to Rs 455.7 crore, missing analysts' estimates. In the same quarter last year net profit was Rs 518.5 crore.
Total income rose 16 percent to Rs 4,294 crore in Q1FY19 compared to previous year's Rs 3,700 crore.
The revenue growth was ledÂ byÂ Europe,Â driven by theÂ acquisition of Generis Farmaceutica, theÂ Portugal company that Aurobindo bought from Magnum Capital Partners for â‚¬135 million (around Rs 969 crore).
Analysts polled by Reuters saw net income of the country's second-largest drug maker at RsÂ Â 539 .5 crore and revenues at Rs 4,091.8 crore for the first quarter of FY19.